2023 World Conference on Lung Cancer (Posters)-EP07.05. Neoadjuvant Chemotherapy or Chemo-IO in Resectable KRAS-Mutated Non-small Cell Lung Cancer (NSCLC) Patients: Single Center Experience

EP07.05. Neoadjuvant Chemotherapy or Chemo-IO in Resectable KRAS-Mutated Non-small Cell Lung Cancer (NSCLC) Patients: Single Center Experience - PDF(Abstract)

Back to course

Pdf Summary

The abstract provides a summary of a single-center retrospective analysis on the outcomes of neoadjuvant chemotherapy or chemo/immunotherapy in patients with resectable KRAS-mutated non-small cell lung cancer (NSCLC). The study aimed to assess the major pathological response (MPR), pathological complete response (pCR), event-free survival (EFS), and overall survival (OS) in these patients.<br /><br />The study included 69 patients with resectable KRAS-mutated NSCLC who received neoadjuvant chemotherapy or chemo/immunotherapy at the MD Anderson Cancer Center. The median age of the patients was 66, with 57% being female. Of the patients, 42% had the KRAS G12C mutation, and 22% received chemo/IO. MPR was observed in 22% of patients, with three cases of pCR. The percentage of MPR was higher in patients who received chemo/IO compared to chemo alone. The study found that achieving MPR was associated with longer EFS and OS.<br /><br />The analysis also included the assessment of the impact of STK11 and TP53 co-mutations on outcomes. It was found that STK11 co-mutation correlated with lower MPR percentage, shorter EFS, and OS. However, TP53 co-mutation did not have a clinically significant impact on MPR, EFS, or OS. The presence of the KRAS G12C mutation trended towards better OS without statistical significance.<br /><br />In conclusion, the study demonstrated that neoadjuvant chemo/IO was associated with higher MPR in KRAS-mutated NSCLC patients compared to chemo alone. Achieving MPR was associated with longer EFS and OS. The study suggests that future research is needed to identify the optimal neoadjuvant therapy for KRAS-mutated NSCLC patients.

Asset Subtitle

Kaiwen Wang

Meta Tag

Speaker Kaiwen Wang

Topic Early-Stage NSCLC: Pushing the Boundaries

Keywords

neoadjuvant chemotherapy

chemo/immunotherapy

KRAS-mutated non-small cell lung cancer

major pathological response

pathological complete response

event-free survival

overall survival

STK11 co-mutation

TP53 co-mutation

KRAS G12C mutation